The size of the MEA tumor ablation market is predicted to be growing at a CAGR of 11.66% from 2022 to 2027. The size of the market was worth USD 0.07 Billion in 2022 and is predicted to be USD 0.12 Billion by 2027.
Tumors are the group of abnormal cells that accumulate together and form lumps. Tumor ablation is a minimally invasive procedure that destroys cancer cells in the chest, lung, and liver.
The rising Prevalence of cancer is proportional to the growth of the tumor ablation market. According to the recent statistics published by the WHO, cancer accounts for 13% of deaths worldwide. Cancer incidence is expected to increase by 70% over the next couple of decades.
Middle-East & Africa tumor ablation market is driven by factors such as the growing aging population and the increasing number of people affected with cancer. In addition, increasing demand for minimally invasive cancer treatment procedures and raising awareness about the benefits offered by ablation procedures over conventional surgical procedures are also critical factors adding up to the growth of the market.
However, crucial challenges related to ablation procedures and strict regulatory guidelines hinder the growth of the market.
This research report on the MEA tumor ablation market has been segmented and sub-segmented into the following categories:
By Technology:
By Treatment:
By Application:
By Country:
Regionally, Middle East accounted for the largest share of the market in 2020 due to high disposable income and widespread awareness about various ablation procedures. In contrast, Africa is estimated to be the fastest-growing region with a CAGR of XX% due to the high prevalence of the disease in the area.
The South Africa tumor ablation market is estimated to be the rapidly growing regional market in the MEA region. This increases the disease occurrence rate and raises awareness regarding the advantages provided by the ablation procedures over conventional surgical procedures. Moreover, the government has taken some initiatives to bring awareness of different cancer types, which drives the tumor ablation growth in this MEA region.
KEY MARKET PLAYERS:
Some of the notable companies in the MEA tumor ablation market profiled in this report are Medtronic Plc., Boston Scientific Corporation, Angiodynamics, Mermaid Medical, HealthTronics, Galil Medical Inc., EDAP TMS S.A., SonaCare Medical, Misonix, Inc. and Neuwave Medical, Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com